SCHEMBL578432

SCHEMBL578432

NC(=O)CN1C(=O)Cc2ccccc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.50
HTR7 P34969 10/20 0.48
PRMT5 O14744 1/20 0.46
WDR77 Q9BQA1 1/20 0.46
HTR1A P08908 4/20 0.46
ALDH1A1 P00352 2/20 0.45
KMT2A Q03164 2/20 0.45
KDM4E B2RXH2 1/20 0.45
MEN1 O00255 1/20 0.45
CYP3A4 P08684 1/20 0.45
MAPT P10636 1/20 0.45
PABPC1 P11940 1/20 0.45
BLM P54132 1/20 0.45
DRD2 P14416 2/20 0.45
HPGD P15428 1/20 0.45
DRD5 P21918 1/20 0.45
DRD3 P35462 1/20 0.45
CYP2C19 P33261 1/20 0.44
DRD4 P21917 1/20 0.44
PER2 O15055 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3785481 0.85 POLB (0.58) ALDH1A1KDM4ECYP3A4MAPTDRD2
SCHEMBL5966716 0.85 MEN1 (0.52) NOTUMHTR7PRMT5WDR77HTR1A
SCHEMBL29963849 0.85 MEN1 (0.52) NOTUMHTR7PRMT5WDR77HTR1A
SCHEMBL19410673 0.83 NOTUM (0.58) NOTUMHTR7PRMT5WDR77HTR1A
SCHEMBL11645408 0.81 KMT2A (0.59) ALDH1A1KMT2AKDM4EMEN1CYP3A4
SCHEMBL4422479 0.80 NOTUM (0.50) NOTUMHTR7PRMT5WDR77HTR1A
SCHEMBL2954869 0.79 HTR7 (0.53) NOTUMHTR7PRMT5WDR77HTR1A
SCHEMBL19410662 0.79 NOTUM (0.53) NOTUMHTR7PRMT5WDR77HTR1A
SCHEMBL661562 0.78 KMO (0.44) NOTUMKMT2AKDM4EMEN1MAPT
SCHEMBL664077 0.78 HDAC1 (0.44) ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE47731-E1 Kinase inhibitors and method of treating cancer with same UNIV HEALTH NETWORK (CA) 2019-11-19 US disclosed
US-RE47731-E1 Kinase inhibitors and method of treating cancer with same UNIV HEALTH NETWORK (CA) 2019-11-19 US disclosed
US-10358436-B2 Kinase inhibitors and method of treating cancer UNIVERSITY HEALTH NETWORK (CA) 2019-07-23 US disclosed
US-10358436-B2 Kinase inhibitors and method of treating cancer UNIVERSITY HEALTH NETWORK (CA) 2019-07-23 US disclosed
US-20180282306-A1 KINASE INHIBITORS AND METHOD OF TREATING CANCER UNIVERSITY HEALTH NETWORK (CA) 2018-10-04 US disclosed
US-9907800-B2 Kinase inhibitors and method of treating cancer UNIVERSITY HEALTH NETWORK (CA) 2018-03-06 US disclosed
US-9907800-B2 Kinase inhibitors and method of treating cancer UNIVERSITY HEALTH NETWORK (CA) 2018-03-06 US disclosed
US-9907800-B2 Kinase inhibitors and method of treating cancer UNIVERSITY HEALTH NETWORK (CA) 2018-03-06 US disclosed
EP-2556071-B1 KINASE INHIBITORS AND THEIR USE IN TREATING CANCER UNIV HEALTH NETWORK (CA) 2016-08-17 EP disclosed
US-20160045511-A1 KINASE INHIBITORS AND METHOD OF TREATING CANCER UNIVERSITY HEALTH NETWORK (CA) 2016-02-18 US disclosed
US-7645887-B2 2-(5-iodo-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide; epilepsy, epileptogenesis, seizure disorders and convulsion; 2-(5-chloro-2-oxo-2,3-dhydro-1H-indol-1-yl)-N-[6-(hydroxymethyl)cyclohex-3-en-1-yl]acetamide UCB PHARMA, S.A. (BE) 2010-01-12 US disclosed
US-7632856-B2 Indolone derivatives, processes for preparing them and their uses UCB PHARMA, S.A. (BE) 2009-12-15 US disclosed
US-20090012147-A1 Indolone Derivatives, Processes For Preparing Them And Their Uses UCB PHARMA, S.A. (BE) 2009-01-08 US disclosed
CN-100364973-C Indolone-acetamide derivatives, processes for preparing them and their uses UCB SA (BE) 2008-01-30 CN disclosed
US-20070043038-A1 Indolone-acetamide derivatives, processes for preparing them and their uses UCB, S.A. (BE) 2007-02-22 US disclosed
US-20070043038-A1 Indolone-acetamide derivatives, processes for preparing them and their uses UCB, S.A. (BE) 2007-02-22 US disclosed
US-20070043038-A1 Indolone-acetamide derivatives, processes for preparing them and their uses UCB, S.A. (BE) 2007-02-22 US disclosed
CN-1768036-A Indolone-acetamide derivatives, processes for preparing them and their uses UCB SA (BE) 2006-05-03 CN disclosed
EP-1620399-A1 INDOLONE-ACETAMIDE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB, S.A. (BE) 2006-02-01 EP disclosed
WO-2004087658-A1 INDOLONE-ACETAMIDE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB, S.A. (BE) 2004-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012147-A1 Indolone Derivatives, Processes For Preparing Them And Their Uses IDO1, IDO2, HTR3C NOTUM 1201/4885HTR7 10/4885PRMT5 1390/4885
US-20160045511-A1 KINASE INHIBITORS AND METHOD OF TREATING CANCER MAP3K6, MAP3K5, MAP3K19 NOTUM 2170/4885HTR7 3327/4885PRMT5 859/4885
US-10358436-B2 Kinase inhibitors and method of treating cancer MAP3K6, MAP3K5, MAP3K19 NOTUM 2170/4885HTR7 3327/4885PRMT5 859/4885
US-20180282306-A1 KINASE INHIBITORS AND METHOD OF TREATING CANCER MAP3K6, MAP3K5, MAP3K19 NOTUM 2170/4885HTR7 3327/4885PRMT5 859/4885
US-20070043038-A1 Indolone-acetamide derivatives, processes for preparing them and their uses AANAT, TPH2, CYP1A2 NOTUM 1090/4885HTR7 294/4885PRMT5 1645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.